Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 42, Issue 7, Pages 567-581Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-019-01140-1
Keywords
Immunotherapy; Immune checkpoint inhibitor; Heterogeneity of T cell exhaustion; Human cancer
Categories
Funding
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
- KAIST Future Systems Healthcare Project from the Ministry of Science and ICT
- National Research Foundation of Korea [NRF-2016H1A2A1906766]
- Ministry of Health & Welfare, Republic of Korea [HI15C2859]
- National Research Foundation of Korea [2016H1A2A1906766] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 therapy are now FDA-approved treatment options for different cancer types. However, the therapeutic efficacy of ICIs varies substantially among cancer types and patients, and only a limited proportion of cancer patients benefit clinically from ICIs. To improve the therapeutic efficacy of cancer treatments involving ICI, the mechanisms of response to ICIs and the heterogeneous pattern of immune checkpoint receptor expression need to be better understood. Here, we review recent studies on ICIs in human cancer, providing the necessary basis for the rational design of immunotherapy and for appropriate patient selection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available